SK bioscience Co.,Ltd. (KRX: 302440)

Market Cap	3.84T
Revenue (ttm)	201.30B
Net Income (ttm)	-43.27B
Shares Out	78.35M
EPS (ttm)	-565.42
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	31,625
Average Volume	133,598
Open	48,500
Previous Close	48,000
Day's Range	48,350 - 49,000
52-Week Range	43,650 - 65,700
Beta	1.20
RSI	42.73
Earnings Date	Jan 27, 2025

About SK bioscience

SK bioscience Co.,Ltd. engages in the research and development, production, and distribution of vaccines and biopharmaceuticals in Korea and internationally. Its product portfolio includes Skycellflu, a cell cultured influenza surface antigen vaccine; Skycellflu 4-ga pre-filled syringe; pneumococcal vaccine for adult and infant; Skyzoster, a shingles virus vaccine; and Sky Baricella for the prevention of chickenpox infection in children. The company also engages in the development of oral rotavirus vaccine that has completed phase 2 clinical tr...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2018
• Employees: 984
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 302440

Financial Performance

In 2023, SK bioscience Co.,Ltd.'s revenue was 369.51 billion, a decrease of -19.10% compared to the previous year's 456.73 billion. Earnings were 22.32 billion, a decrease of -81.77%.